Dose enhancement ratio (as assessed in cell viability assays ).
Radiation therapy is one of the most important treatment modalities for cancer therapy alongside surgery and chemotherapy. However, a major problem associated with radiation therapy in the clinical setting is that, in many cases, local control of the tumor cannot be achieved using this modality alone. This has driven researchers into radiosensitizers, i.e., compounds that enhance the intrinsic sensitivity of cancer cells to ionizing radiation (IR). Several compounds, including halogenated pyrimidines and nitroimidazole derivatives, show radiosensitizing effects in cancer cells ; however, clinical application of these compounds is limited because they are highly toxic to normal cell and tissues. Therefore, radiosensitizers with low toxicity to normal tissues are urgently needed.
The principal target for IR-induced killing of cancer cells is DNA . Of the different types of DNA damage generated by IR, DNA double-strand breaks (DSBs) are thought to be the most cytotoxic. DSBs induced by IR are preferentially repaired by non-homologous end joining (NHEJ) [3, 4], which joins the two broken DNA ends without the need for sequence homology. To enable NHEJ, the chromatin needs to be remodeled into an ‘open’ state so that the DNA repair proteins can access the DSB sites . We previously reported that acetylation of histone proteins at DSB sites by the histone acetyltransferases (HATs), TIP60, CBP and p300, facilitates NHEJ through chromatin remodeling . This suggests that the inhibition of HAT activity will radiosensitize cancer cells by suppressing NHEJ. In line with this, we and others demonstrated that several natural compounds with HAT-inhibitory activity are able to radiosensitize cancer cells [6-12]. Since some of these compounds are safe when administered to humans [13-15], they could potentially be used as radiosensitizers in a clinical setting. Here, we discuss the role of HATs in NHEJ, the radiosensitizing effects of compounds with HAT-inhibitory activity, and the prospects for the clinical application of these compounds.
2. Radiosensitization by HAT inhibition
2.1. HATs are involved in chromatin remodeling required for DNA repair
Chromosomal DNA and histones form a highly condensed structure known as chromatin. During the repair of DNA DSBs, the accessibility of DNA repair proteins to the DSB sites on chromosomal DNA is regulated by the relaxation of the chromosome structure via chromatin remodeling. Remodeling is mediated by both covalent (histone modifications, e.g., acetylation) and non-covalent (ATPase-dependent chromatin remodeling) interactions
2.2. Cell-based NHEJ activity assay
We developed a new assay system for evaluating NHEJ repair of DSBs in the chromosomal DNA in living human cells [6, 18] because the existing NHEJ assays used only non-chromosomal (i.e., plasmid) DNA. The assay design is outlined in Figure 2. The IRES-TK-EGFP plasmid, which contains two recognition sites for
Therefore, the efficiency of NHEJ can be assessed by monitoring EGFP production. In addition, the DSBs produced by
Nucleotide sequencing of the joined DNA revealed that ligation required no (or very little) sequence homology between the DNA ends, indicating that the DNA ends were joined via NHEJ. In addition, the contribution of other factors essential for the NHEJ of incompatible DNA ends (whose involvement was indicated by
2.3. HATs involved in NHEJ
To date, several distinct families of HAT proteins have been identified, including CBP, P300, PCAF, GCN5 and MYST (which includes TIP60) . We investigated the effects of ablating
2.4. Natural compounds with HAT activity suppress NHEJ activity
Several compounds derived from natural ingredients show HAT-inhibitory activity (Table 1). Curcumin, a major curcumanoid found in the spice turmeric, is a specific inhibitor of the homologous HATs, CBP and P300 . Anacardic acid, derived from the shell of
|Compound||MW1||Target HATs||Other target proteins/pathways||DER2|
|Curcumin||368.38||CBP, P300||NF-κB pathway, PI3K/mTOR/ETS2 pathway, AP-1 STAT, LOX-1||1.23|
|Anacardic acid||342.47||P300, PCAF, TIP60||NF-κB pathway, LOX-1, Xanthine oxidase, ||1.51|
|Garcinol||602.80||P300, PCAF||NF-κB pathway, Src, MAPK/ERK, PI3K/Akt pathways, topoisomerase I/II||1.61|
The cell-based NHEJ activity assay was used to investigate the effects of curcumin, anacardic acid, and garcinol on NHEJ; the results showed that treatment with each compound decreased the proportion of EGFP-positive cells (Figure 3) [6, 8]. This indicates that these HAT inhibitors suppress NHEJ activity
2.5. HAT inhibitors radiosensitize cancer cells
Because DNA DSBs induced by IR are preferentially repaired by NHEJ [3, 4], and HAT inhibitors suppress the activity of NHEJ, it is thought that HAT inhibitors may enhance the intrinsic sensitivity of cancer cells to IR. In line with this, the radiosensitizing effects of curcumin, anacardic acid and garcinol have been studied by ourselves and others both
|Curcumin||Cells & mice||SCC1||Khafif A, ||2009||The Laryngoscope|
|Cells||HCT116||Sandur SK, ||2009||Int J Radiat Oncol Biol Phys|
|Cells||PC-3||Li M, ||2007||Cancer Res|
|Cells||PC-3||Chendil D, ||2004||Oncogene|
|Cells||H1299||Ogiwara H, ||2011||Oncogene|
|Anacardic acid||Cells||SQ20B, SCC35, HeLa||Sun Y,||2006||FEBS Lett|
|Garcinol||Cells||A549, HeLa||Oike, ||2012||Int J Radiat Oncol Biol Phys|
2.6. Clinical studies using compounds with HAT-inhibitory activity
There are several clinical studies reporting the administration of compounds with HAT-inhibitory to humans (Table 3). Curcumin has been used, either alone or combined with radiation therapy and/or chemotherapeutic agents, to treat cancer patients, and garcinol has been used for weight-loss therapy. Although not all of the studies were designed to specifically evaluate the radiosensitizing effects of these compounds, the data will be of help to estimate their toxicity. The available data indicate that the side effects of these compounds are tolerable, at least when used alone.
|Curcumin||Rectal cancer*||II||Curcumin, RT1, capecitabine ||M.D. Anderson Cancer Center|
|Curcumin||Pancreatic cancer*||II||Curcumin, gemcitabine ||Rambam Healthcare Campus|
|Curcumin||Pancreatic cancer*||II||Curcumin alone||M.D. Anderson Cancer Center|
|Curcumin||Colorectal cancer||I||Curcumin alone||Sharma RA, et al.|
|Curcumin||Healthy volunteer||I||Curcumin alone||Lao CD, et al.|
|Garcinol||Obesity**||II||Garcinol, HCA2 acid ||Sabinsa Corporation|
|Garcinol||Obesity||II||Garcinol, HCA2, forskolin, piperine||Majeed M, et al.|
The growing incidence of cancer worldwide indicates that radiation therapy will become increasingly significant as a cancer treatment . Enhancing the efficacy of IR against cancer cells is urgent needs local control of tumors. As discussed in this article, radiosensitization of cancer cells by compounds with HAT-inhibitory activity has been reported at the level of basic research. Clinical studies indicate that some of these compounds can be administered to human patients with low systemic toxicity. Taken together, the available data suggest that compounds with HAT-inhibitory activity are promising candidates for radiosensitizers that may be applicable in clinical settings. However, the detailed mechanisms by which these compounds radiosensitize cancer cells are still largely unknown. Moreover, it is unclear whether these compounds can achieve adequate levels of radiosensitization in humans at a dose that shows no (or at least low) toxicity. Further investigations will establish whether HAT inhibitors can be used clinically to radiosensitize cancer cells.
This work was supported by Grants-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan for Scientific Research on Innovative Areas (22131006) and from the Japan Society for the Promotion of Science for Young Scientists (B) KAKENHI (23701110); and the National Cancer Center Research and Development Fund.
Hall E. J. Giaccia A. J. 2006Radiosensitizers and bioreductive drugs. In: McAllister L, Bierig L, Barret K, editors. Radiobiology for the radiologist. Philadelphia: Lippincott Williams & Wilkins. 419 431
Hall E. J. Giaccia A. J. 2006DNA strand breaks and chromosomal aberrations. In: McAllister L, Bierig L, Barret K, editors. Radiobiology for the radiologist. Philadelphia: Lippincott Williams & Wilkins. 16 29
Chen BPC, Chen DJ, et al. ( Burma S. 2006 Role of non-homologous end joining (NHEJ) in maintaining genomic integrity
Lieber M. R. 2008 The mechanism of human nonhomologous DNA end joining.J. Biol. Chem. 283 1 5
Rossetto D. Truman A. W. Kron S. J. et al 2010 Epigenetic modifications in double-strand break DNA damage signaling and repair.Clin. Cancer. Res. 15 4543 4552
Ogiwara H. Ui A. Otsuka A. et al 2011 Histone acetylation by CBP and 300at double-strand break sites facilitates SWI/SNF chromatin remodeling and the recruitment of non-homologous end joining factors.
Sun Y. Jiang X. Chen S. et al 2006 Inhibition of histone acetyltransferase activity by anacardic acid sensitizes tumor cells to ionizing radiationFEBS Lett. 580 4353 4356
Oike T. Ogiwara H. Torikai K. et al 2012 Garcinol, a histone acetyltransferase inhibitor, radiosensitizes cancer cells by inhibiting non-homologous end joining.Int. J. Radiat. Oncol. Biol. Phys. in press.
Khafif A. Lev-ari S. Vexler A. et al 2009 Curcumin: a potential radio-enhancer in head and neck cancer.Laryngoscope. 119 2019 2026
Sandur S. K. Deorukhkar A. Pandey M. K. et al 2009 Curcumin modulates the radiosensitivity of colorectal cancer cells by suppressing constitutive and inducible NF-?B activity. Int.J. Radiat. Oncol. Biol. Phys. 75 534 542
Mao LiZhuo Zhang, Donald L. Hill, et al. ( 2007Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Cancer Res. 67 1988 96
Chendil D. Ranga R. S. Meigooni D. et al 2004 Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3.
Sharma R. A. Euden S. A. Platton A. L. et al 2004 Phase I clinical trial of oral curcumin biomarkers of systemic activity and compliance.Clin. Cancer Res. 10 6847 1854
Lao C. D. Ruffin M. T. Normolle D. et al 2006 Dose escalation of a curcuminoid formulationBMC Complment Altern. Med. 6:10.
Majeed M. Badmaev V. Khan N. et al 2009A new class of phytonutrients for body weight management. NUTRAfoods 8 17 26
Bird A. W. Yu D. Y. Pray-grant M. G. et al 2002 Acetylation of histone H4 by Esa1 is required for DNA double-strand break repair.
Tamburini B. A. Tyler J. K. 2005 Localized histone acetylation and deacetylation triggered by the homologous recombination pathway of double-strand DNA repair.Mol. Cell. Biol. 25 4903 4913
Murr R. Loizou J. I. Yang Y. G. et al 2006 Histone acetylation by Trrap-Tip60 modulates loading of repair proteins and repair of DNA double-strand breaks.Nat. Cell. Biol. 8 91 99
Lan L. Ui A. Nakajima S. Hatakeyama K. Hoshi M. Watanabe R. Janicki S. Ogiwara H. Kohno T. Kanno S. Yasui A. The ACF1 complex is required for DNA double-strand break repair in human cells.Mol Cell 2010 976 EOF 87 EOF
Jasin M. 1996 Genetic manipulation of genomes with rare-cutting endonucleases.Trends Genet. 12 224 228
Ogiwara H. Kohno T. Essential factors for incompatible DNA end joining at chromosomal DNA double strand breaks in vivoPLoS One, 2011e28756.
PALF acts as both a single-stranded DNA endonuclease and a single-stranded DNA 3’-exonuclease and can participate in DNA end joining in a biochemical system. J Biol Chem. Li S. Kanno S. Watanabe R. Ogiwara H. Kohno T. Watanabe G. Yasui A. Lieber M. R. 2011
Carrozza M. J. Utley R. T. Workman J. L. et al 2003 The diverse functions of histone acetyltransferase complexes.Trends Genet. 19 321 329
Balasubramanyam K. Varier R. A. Altaf M. et al 2004 Curcumin, a novele acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J. Biol. Chem. 279:51163-51171. 300CREB-binding protein-specific inhibitor of acetyltransferase, represses th
. ( , Hemshekhar M , Sebastin SM , Kemparaju K et al 2011) Emerging roles of anacardic acid and its derivatives: a pharmacological overview. Basic Clin. Pharmacol. Toxicol. doi:10.1111/j. 1742 7843.2011.00833.x. [Epub ahead of print]
Balasubramanyam K. Swaminathan V. Ranganathan A. et al 2003 Small molecule modulators of histone acetyltransferase 300J. Biol. Chem. 278:19134-19140.
Balasubramanyam K. Altaf M. Varier R. A. et al 2004Polyisoprenylated benzphenone, garcinol, anatural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression. J. Biol. Chem. 279 33716 33726
and Boyle P. Leon B. 2008 World Cancer Report 2008Lyon: International agency for research on Cancer, World Health Organization. 15 p.